Biocon Biologics

NEW DELHI: () retail investors continued to lose their worth of investments for the fourth day after listing as the stock fell another 2 per cent on Friday to close down near all-time lows.…

New Delhi: Biocon Biologics, a subsidiary of Biocon, will file for an initial public offer (IPO) within next two years, Executive Chairperson Kiran Mazumdar-Shaw said on Monday. Biocon…

Shares of Biocon slipped 8 per cent to Rs 363.45 on the BSE in Monday’s intra-day trade after Biocon Biologics (BBL), the…

Kiran Mazumdar-Shaw, founder and executive chairperson of Biocon, said the deal will fast-track the company’s journey to build Biocon into a global brand. Following the deal, Mazumdar-Shaw…

Drugmaker is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and profit growth in the next several quarters, primarily from…

Biocon’s partner US-based Equillium Inc has expanded its ‘EQUALISE’ study in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis for Itolizumab to clinical centers in India, Biocon Ltd…

Hi there, Good Morning. Welcome to ETMarkets Morning, the show about money, business and markets. I am Nikhil Agarwal. Let's start with the headlines first.- GST Council meeting to be held…

For the first time, U.S. regulators have said that a knockoff version of a biologic drug is interchangeable with its branded equivalent, a milestone in the yearslong effort to…